# Design Therapeutics (DSGN) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/DSGN
## Company Profile
- Ticker: DSGN
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 14.66 USD
- Market cap: 635187425.58 USD
- Last updated: 2026-08-12
## Business Overview
### GeneTAC Platform
Design Therapeutics develops GeneTAC small molecules that bind genomic repeat sequences and modulate transcription. The platform is designed either to increase expression of a deficient gene or reduce expression of a toxic mutant gene.
### DT-216P2
DT-216P2 is being developed for Friedreich ataxia and is designed to increase endogenous frataxin expression. The Phase 1/2 RESTORE-FA trial measures safety, pharmacokinetics and changes in frataxin RNA and protein in blood and muscle.
### DT-168
DT-168 is in a Phase 2 biomarker trial for Fuchs endothelial corneal dystrophy. The study evaluates corneal-endothelium biomarkers in patients already scheduled for transplant surgery.
### DT-818
DT-818 is designed to selectively reduce transcription of the mutant DMPK allele in myotonic dystrophy type 1. A Phase 1 multiple-ascending-dose trial will assess safety and correction of disease-associated RNA mis-splicing.
### Earlier Genetic-Disease Pipeline
Design is also characterizing GeneTAC candidates for Huntington’s disease and conducting discovery work across additional genomic disorders.
## Why The Stock Is Moving

As of Aug 12, 2026, DSGN closed up 0.27% at $14.66. No new same-company headline was identified in the current news window.

## Future Catalysts

- Initial dosing in the Phase 1 DT-818 trial planned in the first half of 2026, with results expected in 2027.
- DT-216P2 frataxin biomarker update expected in the second half of 2026.
- Phase 2 biomarker data for DT-168 expected in the second half of 2026.

## Drug Assets

- DT-216P2

## Recent News
- 2026-08-03 12:00 EST — [Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/DSGN/design-therapeutics-provides-restore-fa-clinical-development-update-and-reports--ceffa181) — Source: Design Therapeutics
- 2026-06-30 12:00 EST — [Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1](https://biopharmsignal.com/news/DSGN/design-therapeutics-announces-initiation-of-patient-dosing-in-phase-1-multiple-a-1d18e89a) — Source: Design Therapeutics
- 2026-05-28 12:00 EST — [Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/DSGN/design-therapeutics-to-participate-in-2026-jefferies-global-healthcare-conference) — Source: Design Therapeutics
- 2026-05-18 11:00 EST — [Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia](https://biopharmsignal.com/news/DSGN/design-therapeutics-announces-four-week-iv-data-from-the-restore-fa-trial-of-dt-216p2-demonstrating-clinical-improvements-and-comprehensive-biomarker-activity-in-friedreich-ataxia) — Source: Design Therapeutics
- 2026-05-17 20:00 EST — [Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026](https://biopharmsignal.com/news/DSGN/design-therapeutics-to-host-investor-webcast-to-review-data-from-restore-fa-trial-of-dt-216p2-for-friedreich-s-ataxia-on-monday-may-18-2026) — Source: Design Therapeutics